Read the records behind the answers

Reading by question

• Find a physician’s public record

  Use the directory published by the medical-board group, the Federation of State Medical Boards. Choose a state link that matches your doctor’s degree. The letters MD stand for Doctor of Medicine, while DO stands for Doctor of Osteopathic Medicine, another medical degree. Some states license them through separate boards. Use the board’s own search for the name you were given. Boards publish license status and public discipline information, but the amount of detail varies. A record without public action is not a grade for the care. Keep the result link and ask the board about unclear terms.

• Read about care across state lines

  Federal health guidance describes licenses, registrations, and other routes for remote care across state lines. It is an overview, not a permission for a particular professional to treat someone anywhere. For a proposed visit, ask how the route fits the state where you will be. The state’s own board remains the place to resolve a question about a specific record or registration.

• See what an online assessment calls for

  The board group’s report covers visits conducted from separate places. It describes identity checks, an exchange that can gather further history, and the need to arrange more assessment when the visit requires it. It offers advice for boards to use when writing their own rules. States adopt and enforce their own rules. Its distinction between a fixed form and a responsive exchange is useful when asking how an online visit will work.

• Separate compounding from product approval

  The Food and Drug Administration’s (FDA) questions describe the preparation of medicines to order, called compounding. The September 2026 position was that compounded preparations lacked FDA approval and a premarket review of quality, safety, and effectiveness. Keep that limit beside the stated medical need. It does not make compounding itself prohibited, nor does a pharmacy license grant approval to each preparation.

• Read the ingredient’s record

  FDA’s table page is marked current April 22, 2026. A reader will find separate tables for Category 2 and withdrawn requests. Category 2 records ingredients with significant safety concerns. The withdrawn table shows requests taken back by the people who submitted them, with FDA’s safety warnings kept in place. No dates are given for individual withdrawals. That withdrawal does not give FDA approval or establish safe use. On October 30, 2026, HHS published a separate draft for semax, KPV, TB-500, MOTS-c, BPC-157 and epitalon. It describes when the department does not intend to act against physicians or pharmacies with a state license making one of these peptides for a patient named on a prescription. A prescription alone is not enough: the draft’s other conditions also have to be met. A blend is outside its scope, as is a 503B outsourcing facility. Those facilities make sterile medicines in batches, with sterile meaning no living germs. The six have not been added to FDA’s list of additional compounding ingredients, called the 503A bulks list. The department is not required to follow this draft, and it gives no FDA approval to a medicine. Ask how the exact ingredient and proposed way of using it fit the conditions.

• Read the draft HHS policy

  The policy’s conditions and ingredient limits matter for an actual prescription. As of November 3, 2026, FDA had not posted meeting minutes or a transcript for its July 23–24, 2026 advisory meeting. HHS’s October 30, 2026 account reports favorable committee votes for six peptides out of seven. It gives no roll-call totals. A committee vote advises FDA; it does not by itself change the ingredient list or approve a medicine.

• Check the pharmacy named in the plan

  Through BeSafeRx, FDA gives readers state links for pharmacy license searches. Search for the source that would prepare or send the medicine, even when a different service arranged the visit. The listing can confirm the license. It cannot assess each product or decision about dispensing. Bring a name mismatch to the board and request help with finding the right record.

• Read the temporary Medicare payment rules

  The Medicare GLP-1 Bridge page describes a temporary route outside the usual Part D payment process. Its eligibility and product rules matter as much as its headline copay. It is not coverage for everyone who asks about weight medicine. Keep the medicine’s exact name and the proposed medical use beside the plan details. Ask the plan and prescriber to check the applicable route.

• Find product-help and reporting information

  MedWatch is FDA’s public medical-product reporting program. It records unwanted experiences without establishing whether a drug caused them. Reports also cannot show how often an event happens. Someone who needs help now still needs personal assessment. The National Library of Medicine directs personal health questions to a qualified professional, beyond what general pages can provide.